Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Jeff! Merry Merry to you and all of the faithful posters on this board!
Why is Karen Quinn's ANI Pharma linkedin location Miami?
https://nz.linkedin.com/in/karen-quinn-b56a217
https://www.lawleypharm.com.au
Lawley makes Androfeme and it's approved in Australia. Check out this website. They are planning to get FDA approval. They take a strong stand against compounding and site lawsuits to threaten compounders from using their products. Susan Davis and Monash U work with Lawley.
JTFM
Wondered the same. Also wonder which company holds Intrinsa IP. Warner Chilcott was selling Intrinsa in the UK before it was discontinued. Could P&G still have the IP?
JTFM,
I'd forgotten about Karen Quinn and so I'm posting this PR for anyone else who needs a refresher:
https://finance.yahoo.com/news/ani-announces-appointment-karen-quinn-133000278.html
Worked for Solvay, P & G. I agree that she is very valuable for more than corti drug!
ANIP seems to favor Thursday announcements.
Have you seen today's volume? Seriously.
Maybe we will get some info this week.
North,
To have suffered with T1 D for sixty five years and be so healthy with amazing bloodwork, wow!
Omega 3 fatty acids are really lacking in our modern diet and they do appear to help everything by reducing inflammation.
This is the product I love: http://www.barleans.com/swirls/fish-oil-omega-swirl-lemon-zest-flavor-16oz-be16fl?sma=sm.00000matt1rhy3cpizzksb3kspiiy
I think it's great that you shared your success with researchers.
I don't however, see Vascepa competing with a testosterone replacement product for women who are surgically menopausal (if that's what you meant).
I'm sure it's all related. Low T= reduced muscle mass, decreased physical activity, depression, weight gain, etc. Those are all associated with the hypertension list on the pdf. Thanks.
Thanks JTFM. If low T does not lead to hypertension, it has been documented as a problem in other CV conditions: http://jaha.ahajournals.org/content/6/5/e004880
Monday should be interesting after last night's tax plan vote.
Serious volume! Now what?
Hi Jeff,
Yes! Hope you had a nice holiday too! Haven't been here as long as you but I've been here long enough to know this is a multi layered asset! Best of luck!
Sandrino,
Hard to assume another investor's "finish line."
I need to stop thinking about this! Too much else to do!
Abbvie acquired Dr. Snabes. ANIP and ATRS hold intellectual property. Could TEVA have acquired the Intrinsa efficacy data from their Allergan deal? It's hard to find a trail on that.
Good summary by Susan Davis of known research to date. Can you imagine her frustration after decades of scientific research? At least her country, Australia, has approved a product:Androfeme.
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(15)00207-7/fulltext
Best to all of you.
Years ago Stephen Simes was trying to find an Israeli company to merge with Biosante in hopes of getting the company on the TASE:
http://www.globes.co.il/en/article-1000219482
According to the article, at that time TEVA owned 20% of Biosante.
TEVA just announced that it will lay off 25% of its workforce. They need a revenue boost asap. Could this surge be related to TEVA? A merger that could get us on the TASE as well as NASDAQ? I think I remember that we own the Israeli rights to Libigel. That was established way back when.
Hoping this turns out very well for all of us!
lol!
Right back at you! A peaceful holiday to all!
Good luck to you too.
Absolutely! Transdermal hormone therapy is far superior to pill. Thanks JTFM.
It could be argued that management is already selling your "love gel" as a pill and making lots of $: eemt
Here's another indication: fibromyalgia. There is a patent.
https://fibromyalgianewstoday.com/2015/10/22/testosterone-gel-relieves-the-symptoms-of-fibromyalgia/
JTFM, Well done! Thank you. Also appreciated your exchange with Loko in the comments of the recent ATRS S.A. article. Pins and needles for now.
Ha! Contacting local media was a great idea!
Not that we distrust the management in charge of our investment but there are big money players behind ANIP who are strictly self-serving.
IMO, the more eyes watching how this transpires, the better.
Beaudette Minnesota strikes me as the kind of small town where news travels very fast. The sale of the town's major employer is probably causing a stir. I don't think Mr. Przybyl is planning to cause his workforce undue anxiety during the holidays. We may hear soon about the direction of this.
Thanks!
Hi Silvr, Please explain how the 2016 write off will affect 4Q. Thanks.
Thanks for that thoughtful response. I'm just trying to consider as many angles as possible. After all this time, change is coming and I too am grateful that we have Mr. Przybyl as our CEO.
JTFM,
Q: Could this mean that they are going private vs. public?
Thanks.
Thanks JTFM! Sure sounds like it.
They don't have much in the way of available jobs either.
Thank you for that article. J
Thanks Jeff. A. Przybyl and co. know how to beat competition!
I'm thinking it's TEVA.
I agree that ANI is a very successful, fast-growing company with fantastic management! Libigel development not really necessary for continued growth.
Your argument against testosterone therapy for women is weak and uninformed. It has taken way too long but the chances of approval for this product have never been better. ANI owns much of the IP for testosterone therapy for women and monetized, it has block buster potential. Read-up my friend!!
The summary of this report mentions T therapy for women. Companies mentioned are Antares (ANI implied) and Abbvie, among others.
https://www.whatech.com/market-research/medical/398301-research-details-developments-in-the-us-testosterone-market-forecast-from-2017-to-2021
What do we know for certain before earnings?
They are still running 2 shifts.
They only have 4 jobs posted.
They recently landed a good sized government contract for vancomycin.
They received fda approval for 1 new (minor) product since last quarter.
They must be finished or close to finished with their building expansion in Beaudette.
Get well soon, BB! Only hurts when you laugh!
Thanks BB. Gotta love Blackrock!
I can think of a couple of companies that would probably be willing to offer ANI lots of money not to produce acthar gel.
As valuable as Libigel data and IP are, acthar is a staggeringly expensive drug.